Literature DB >> 20069559

First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk.

A Khalil1, N J Cowans, K Spencer, S Goichman, H Meiri, K Harrington.   

Abstract

OBJECTIVE: To investigate the predictive value of the combination of first-trimester serum placental protein 13 (PP13), uterine artery Doppler pulsatility index (PI) and pulse wave analysis (augmentation index at a heart rate of 75 beats per min (AIx-75)), and to evaluate concurrent and contingent strategies using this combination for assessing the risk of pre-eclampsia in high-risk women.
METHODS: In this nested case-control study, serum PP13, uterine artery mean PI and AIx-75 were measured at between 11 + 0 and 13 + 6 weeks' gestation in women at increased risk of pre-eclampsia. For each case of pre-eclampsia (n = 42), five matched controls were randomly selected from the study group. Gestation specific multiples of the median (MoMs) were adjusted for body mass index, ethnicity, smoking, age and parity. MoMs were compared between cases and controls using the Wilcoxon rank sum test. Sensitivities and specificities were derived from receiver-operating characteristics curves.
RESULTS: Compared with controls, women who developed pre-eclampsia had lower PP13, higher uterine artery mean PI and higher AIx-75 (P < 0.001). For a 10% false-positive rate, the best detection rate for pre-eclampsia (85.7% (95% CI, 71.5-94.6%)) and pre-eclampsia requiring delivery before 34 weeks (92.9% (95% CI, 66.1-99.8%)) was achieved by concurrent testing with all three markers. The best contingency screening sequences for pre-eclampsia were (AIx-75 --> PP13 --> mean PI) and (PP13 --> AIx-75 --> mean PI), with an 86% detection rate for false-positive rates of 9 and 10%, respectively. These two sequences would require 410 and 414 tests, respectively, compared with 756 tests in concurrent testing.
CONCLUSION: Combination of first-trimester PP13, uterine artery mean PI and pulse-wave analysis is promising for the prediction of pre-eclampsia in women at increased a-priori risk and may be useful in clinical practice. Contingency screening achieved similar detection rates to concurrent testing, but required almost 50% fewer tests, making it a more cost-effective option. (c) 2010 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20069559     DOI: 10.1002/uog.7559

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  17 in total

Review 1.  Galectins: guardians of eutherian pregnancy at the maternal-fetal interface.

Authors:  Nandor Gabor Than; Roberto Romero; Chong Jai Kim; Michael R McGowen; Zoltan Papp; Derek E Wildman
Journal:  Trends Endocrinol Metab       Date:  2011-10-27       Impact factor: 12.015

2.  First-trimester placental protein 13, PAPP-A, uterine artery Doppler and maternal characteristics in the prediction of pre-eclampsia.

Authors:  A O Odibo; Y Zhong; K R Goetzinger; L Odibo; J L Bick; C R Bower; D M Nelson
Journal:  Placenta       Date:  2011-06-08       Impact factor: 3.481

3.  First trimester serum analytes, maternal characteristics and ultrasound markers to predict pregnancies at risk for preterm birth.

Authors:  M J Stout; K R Goetzinger; M G Tuuli; A G Cahill; G A Macones; A O Odibo
Journal:  Placenta       Date:  2012-11-28       Impact factor: 3.481

4.  Changes in Central Hemodynamics in Women With Hypertensive Pregnancy Between Before and After Delivery.

Authors:  Taishi Fukushima; Kazuo Eguchi; Akihide Ohkuchi; Hiroshi Miyashita; Kazuomi Kario
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-09-23       Impact factor: 3.738

5.  PP13, maternal ABO blood groups and the risk assessment of pregnancy complications.

Authors:  Nandor Gabor Than; Roberto Romero; Hamutal Meiri; Offer Erez; Yi Xu; Federica Tarquini; Laszlo Barna; Andras Szilagyi; Ron Ackerman; Marei Sammar; Tibor Fule; Katalin Karaszi; Ilona Kovalszky; Zhong Dong; Chong Jai Kim; Peter Zavodszky; Zoltan Papp; Ron Gonen
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240

Review 6.  Pre-eclampsia and the foetus: a cardiovascular perspective.

Authors:  Ismail Bhorat
Journal:  Cardiovasc J Afr       Date:  2018 Nov/Dec       Impact factor: 0.802

7.  Predictive performance of first trimester serum galectin-13/PP-13 in preeclampsia screening: A systematic review and meta-analysis.

Authors:  Ingrid-Andrada Vasilache; Alexandru Carauleanu; Demetra Socolov; Roxana Matasariu; Ioana Pavaleanu; Dragos Nemescu
Journal:  Exp Ther Med       Date:  2022-04-05       Impact factor: 2.751

Review 8.  Galectins: Double-edged Swords in the Cross-roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia.

Authors:  Nandor Gabor Than; Roberto Romero; Andrea Balogh; Eva Karpati; Salvatore Andrea Mastrolia; Orna Staretz-Chacham; Sinuhe Hahn; Offer Erez; Zoltan Papp; Chong Jai Kim
Journal:  J Pathol Transl Med       Date:  2015-05-15

9.  A cohort evaluation on arterial stiffness and hypertensive disorders in pregnancy.

Authors:  Wai Yee Lim; Seang Mei Saw; Kok Hian Tan; George S H Yeo; Kenneth Y C Kwek
Journal:  BMC Pregnancy Childbirth       Date:  2012-12-26       Impact factor: 3.007

10.  Evaluation of serum β-hCG and PAPP-A levels in pregnant women at risk of developing preeclampsia.

Authors:  Mihaela Daniela Oancea; Nicolae Costin; Daria Maria Pop; Razvan Ciortea; Dan Mihu
Journal:  Clujul Med       Date:  2013-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.